CWA Asset Management Group LLC Makes New Investment in Medpace Holdings, Inc. (NASDAQ:MEDP)

CWA Asset Management Group LLC bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 3,913 shares of the company's stock, valued at approximately $1,306,000.

Several other large investors have also added to or reduced their stakes in MEDP. Private Advisor Group LLC boosted its holdings in Medpace by 10.1% during the first quarter. Private Advisor Group LLC now owns 1,065 shares of the company's stock worth $430,000 after purchasing an additional 98 shares during the last quarter. Janney Montgomery Scott LLC lifted its stake in Medpace by 7.5% in the first quarter. Janney Montgomery Scott LLC now owns 7,630 shares of the company's stock valued at $3,084,000 after acquiring an additional 532 shares during the last quarter. SG Americas Securities LLC lifted its stake in Medpace by 351.5% in the first quarter. SG Americas Securities LLC now owns 15,002 shares of the company's stock valued at $6,063,000 after acquiring an additional 11,679 shares during the last quarter. Swiss National Bank lifted its stake in Medpace by 0.4% in the first quarter. Swiss National Bank now owns 48,400 shares of the company's stock valued at $19,561,000 after acquiring an additional 200 shares during the last quarter. Finally, Sei Investments Co. lifted its stake in Medpace by 12.7% in the first quarter. Sei Investments Co. now owns 135,649 shares of the company's stock valued at $54,822,000 after acquiring an additional 15,304 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on the stock. Jefferies Financial Group cut shares of Medpace from a "buy" rating to a "hold" rating and cut their price target for the company from $415.00 to $345.00 in a research note on Wednesday, September 25th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Medpace from $395.00 to $336.00 and set a "hold" rating for the company in a report on Wednesday, July 24th. Redburn Atlantic initiated coverage on shares of Medpace in a report on Monday, October 14th. They set a "buy" rating and a $404.00 target price for the company. William Blair reaffirmed an "outperform" rating on shares of Medpace in a report on Tuesday, October 22nd. Finally, StockNews.com downgraded shares of Medpace from a "buy" rating to a "hold" rating in a report on Friday, September 27th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $380.00.

Medpace Stock Up 2.7 %

MEDP traded up $9.37 during trading on Friday, hitting $362.79. 358,083 shares of the company traded hands, compared to its average volume of 404,663. The firm has a market cap of $11.28 billion, a P/E ratio of 31.77, a price-to-earnings-growth ratio of 2.01 and a beta of 1.37. The stock's fifty day moving average is $341.59 and its 200 day moving average is $377.29. Medpace Holdings, Inc. has a one year low of $268.80 and a one year high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.24. The company had revenue of $533.32 million during the quarter, compared to analyst estimates of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The firm's revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.22 earnings per share. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.